Informed-money record
ACET · Adicet Bio, Inc.
Disclosed informed-money activity on this name over the last 12 months — corporate insiders, institutions, and members of Congress, from public-domain SEC and congressional filings. A dated factual record with receipts; interpretation is yours.
Bullish filings
5
Bearish filings
7
Named actors
5
Disclosed $ (bull / bear)
$6.6M / $1.9M
Recent disclosures
12 of 12 in the window · linked to source| Date | Who | What | Disclosed $ | Receipt |
|---|---|---|---|---|
| 2026-04-09 | Shareholder (via Themis Trading LLC) OrbiMed Genesis Master Fund, L.P. | filed notice to sell | $514K | SEC ↗ |
| 2026-04-08 | Shareholder (via Themis Trading LLC) OrbiMed Israel Partners II, L.P. | filed notice to sell | $265K | SEC ↗ |
| 2026-04-08 | 10% owner / other ORBIMED ADVISORS LLC | sold | $264K | SEC ↗ |
| 2026-04-08 | 10% owner / other ORBIMED ADVISORS LLC | sold | $205K | SEC ↗ |
| 2026-04-07 | Shareholder (via Themis Trading LLC) OrbiMed Israel Partners Limited Partnership | filed notice to sell | $413K | SEC ↗ |
| 2026-04-07 | 10% owner / other ORBIMED ADVISORS LLC | sold | $191K | SEC ↗ |
| 2026-04-07 | 10% owner / other ORBIMED ADVISORS LLC | sold | $15K | SEC ↗ |
| 2026-02-20 | 10% owner / other RA CAPITAL MANAGEMENT, L.P. | bought | $543K | SEC ↗ |
| 2026-02-19 | 10% owner / other RA CAPITAL MANAGEMENT, L.P. | bought | $535K | SEC ↗ |
| 2026-02-18 | 10% owner / other RA CAPITAL MANAGEMENT, L.P. | bought | $525K | SEC ↗ |
| 2025-10-08 | 10% owner / other ORBIMED ADVISORS LLC | bought | $3.5M | SEC ↗ |
| 2025-10-08 | 10% owner / other ORBIMED ADVISORS LLC | bought | $1.5M | SEC ↗ |
Want the read, not just the record?
Members see how notable each move is, whether the actor's track record validates, cross-source convergence, and alerts on this name.
Create a free account →Dispute or correct this record
Events dated by when the activity occurred (a trade's transaction date; a notice, stake, or announcement at its filing date); the linked filing is the authoritative record. Directional public-domain disclosures only. Descriptive, not investment advice. Methodology · Today's notable signals